GSA Capital Partners LLP Makes New Investment in PepGen, Inc. $PEPG

Key Points

• GSA Capital Partners acquired 852,852 PepGen shares worth approximately $1.535 million, representing a 1.23% stake. Institutional investors collectively own 58.01% of PEPG.
• PepGen reported quarterly EPS of -$0.26, beating analyst expectations of -$0.28; analysts project full-year EPS of -$1.11.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $11.50, compared with the stock’s recent price of $2.99.

GSA Capital Partners LLP purchased a new position in PepGen, Inc. (NASDAQ:PEPG - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 852,852 shares of the company's stock, valued at approximately $1,535,000. GSA Capital Partners LLP owned 1.23% of PepGen at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Seven Fleet Capital Management LP purchased a new stake in PepGen during the 1st quarter worth about $105,000. ADAR1 Capital Management LLC increased its position in shares of PepGen by 4,263.6% during the first quarter. ADAR1 Capital Management LLC now owns 1,607,638 shares of the company's stock valued at $2,846,000 after buying an additional 1,570,796 shares during the period. Kalehua Capital Management LLC bought a new stake in shares of PepGen during the first quarter valued at about $1,770,000. Commodore Capital LP lifted its holdings in shares of PepGen by 31.6% in the first quarter. Commodore Capital LP now owns 4,475,000 shares of the company's stock worth $7,921,000 after buying an additional 1,075,000 shares in the last quarter. Finally, Rangeley Capital LLC lifted its holdings in shares of PepGen by 88.1% in the first quarter. Rangeley Capital LLC now owns 68,096 shares of the company's stock worth $121,000 after buying an additional 31,896 shares in the last quarter. 58.01% of the stock is currently owned by institutional investors.

PepGen Stock Performance

NASDAQ PEPG opened at $2.99 on Monday. PepGen, Inc. has a 52-week low of $1.13 and a 52-week high of $7.80. The company has a market capitalization of $207.09 million, a P/E ratio of -2.28 and a beta of 1.89. The company has a fifty day moving average of $2.01 and a 200-day moving average of $3.02.

PepGen (NASDAQ:PEPG - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. As a group, analysts forecast that PepGen, Inc. will post -1.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on PEPG. HC Wainwright reaffirmed a "buy" rating on shares of PepGen in a research note on Thursday, May 21st. Wall Street Zen raised shares of PepGen from a "sell" rating to a "hold" rating in a report on Sunday, June 7th. Craig Hallum assumed coverage on shares of PepGen in a research report on Tuesday, June 16th. They set a "buy" rating and a $11.00 price target for the company. Weiss Ratings cut shares of PepGen from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 2nd. Finally, Wedbush lowered their price objective on PepGen from $5.00 to $4.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 13th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $11.50.

PepGen Profile

PepGen, Inc NASDAQ: PEPG is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).

Want to see what other hedge funds are holding PEPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PepGen, Inc. (NASDAQ:PEPG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source